Business Wire

NTT to Extend the World’s Largest Connected Stadium to The Tour de France Femmes avec Zwift

28.6.2022 07:00:00 EEST | Business Wire | Press release

Share

NTT Ltd., a leading IT infrastructure and services company, is using technology and innovation to equally enhance the fan experience across both the Tour de France and the Tour de France Femmes avec Zwift.

The 2022 event will see the inaugural women’s race which will start on the Champs-Élysées on July 24th 2022, prior to the conclusion of the men’s race on the same day. The women’s race will feature 24 teams of six riders and will conclude on July 31st 2022 in La Super Planche des Belles Filles. NTT has been the official technology partner of the Tour de France for the past eight years.

For the first time ever, and at a time when interest in women’s cycling is on the rise, NTT will bring fans closer to the action and shine a light on this notable occasion through the implementation of real-time tracking of the riders, the Race Center and its predictive modelling strategy to support the race. The model also includes @letourdata, the data-driven content channel that helps tell the race’s stories over social media and broadcast. Rider and team profiles will uncover unique insights into the women’s pro peloton.

In addition to this, NTT alongside A.S.O. will deliver a host of new and enhanced digital experiences to engage fans around the world, both at home and along the roadside. These experiences include:

  • The Digital Human: NTT has developed an interactive kiosk featuring an AI-generated realistic human avatar, trained on the relevant race and tourist information. This technology will be deployed at the official fan store at the Grand Depart in Copenhagen and in NTT’s Technical Truck at the end of every stage.
  • An enhanced digital twin: Last year, NTT created a digital twin of the event, which enabled staff to gain real-time visibility and ultimately streamline operations to ensure the continuity and resilience of the race. This year, the technology has enhanced connectivity to provide smarter event operations, enabling quicker, more informed decisions in a highly complex and ever-changing environment.
  • Strava partnership: NTT’s live storytelling channel, @letourdata, in collaboration with Strava, will be bringing real-time comparisons between amateurs, pros, and King of the Mountain (or fastest known times) to social media and broadcast during the race.

“With female cycling on the rise as we saw through the 2020 edition of La Course by Le Tour de France avec FDJ with over 30 million TV audience viewers, we’re incredibly proud to continue to help widen the fan base and be part of this historic milestone for female cycling. There is still much more work to be done to achieve equality in cycling, but we’re extremely passionate about doing what we can to increase the accessibility of the sport. Our technology means we can bring the action to more fans than ever before,” says Michele McGuire, Vice President of Managed Services Delivery, Europe at NTT Ltd.

“When it comes to the technology, both races are highly dynamic and require access to real-time information to ensure continuous and smooth operations while creating more informed and engaged fans. NTT’s full stack of solutions and expertise will continue to support the A.S.O. in transforming the famous race,” McGuire adds.

“At A.S.O., we’re extremely proud to be launching Tour de France Femmes avec Zwift and to be able to count on key technical partners such as NTT. Our partnership with NTT is well known for bringing the fans closer to the action. 2022 marks a momentous occasion for women’s cycling, and fans around the world are extremely excited to witness the first edition of the Tour de France Femmes avec Zwift,” said Julien Goupil, Media & Partnerships Director at A.S.O..

NTT’s role as the official technology partner to Tour de France Femmes avec Zwift, means NTT will now support A.S.O. at four of its female events, including Paris-Roubaix Femmes avec Zwift, Flèche Wallonne Femmes, and Liège-Bastogne-Liège Femmes. To find out more about how NTT supports A.S.O., visit: https://services.global.ntt/tourdefrance

Follow @letourdata on Twitter and look for NTT’s race predictions using #NTTPredictor.

ENDS

About Amaury Sport Organisation

Amaury Sport Organisation is a company that owns, designs and organises top international sporting events. Specialised in the ‘non-stadia’ events, it has in-house knowledge of professions linked to organisation, media and sales of sports events. A.S.O. organises 250 days of competition per year, with 90 events in 30 countries. A.S.O. is involved in 5 major sports including cycling with the Tour de France, motor sports with the Dakar, mass events with the Schneider Electric Marathon de Paris, golf with the Lacoste Ladies Open de France and sailing with production and distribution of images for prestigious races. Amaury Sport Organisation is a subsidiary of the Amaury Group, media and sport group that owns the newspaper L’Équipe.

About NTT Ltd.

NTT Ltd. is a leading IT infrastructure and services company. With revenues of over USD 10 billion, we operate in more than 200 countries and regions, and serve 5,000 clients across multiple industries. Through technology and innovation, we deliver a secure and connected future that empowers our people, clients and communities. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments, where networks, cloud and applications converge. On the journey towards a software-defined future, we support organizations with platform-delivered infrastructure services. As part of the global NTT Corporation, we serve 65% of the Fortune Global 500 and 80% of the Fortune Global 100. We enable a connected future.

Visit us at services.global.ntt

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Tour de France - www.letour.fr
Fabrice Tiano
ftiano@aso.fr - +33(0)6.33.86.28.64

Tour de France Femmes avec Zwift - www.letourfemmes.fr
Thida Vuillaume
tvuillaume@aso.fr - +33(0)6.40.29.69.26

Hotwire for NTT Ltd.
Hannah Lock
NTT@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye